Abstract library

45 results for "Ramage".
#2280 The BON-SSTR2 Chicken Chorioallantoic Membrane (CAM) Model for the Analysis of Lu-17-DOTATOC Sensitizing Agents
Introduction: Peptide radioreceptor therapy (PRRT) is a promising therapy option for SSTR2-positive pancreatic neuroendocrine neoplasms (NEN). However, therapeutic effects are often not satisfying concerning sensitivity to PRRT. We hypothesize that the slow proliferation of NENs provides sufficient time for the repair of beta-particle induced-DNA damage. The ubiquitin-proteasome-system is involved in DNA damage repair and affected by the proteasome inhibitor bortezomib (Velcade®). The inhibition of DNA damage repair during PRRT may be an option to improve therapy response in NEN. We have recently demonstrated the damage repair inhibitory and pro-apoptotic effect of bortezomib in NEN in vitro (Briest et al., in revision).
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr. Franziska Briest
#616 Assessment of DNA Double-Strand Breaks in Blood Lymphocytes after Whole-Body Radiation Exposure in Patients with Neuroendocrine Tumors Undergoing 177Lu-Octreotate Therapy
Introduction: Peptide receptor radionuclide therapy using somatostatin receptor-binding peptides, such as 177Lu-Octreotate (LuTate), has been clinically proven to be effective in treating patients with inoperable neuroendocrine tumors. Despite the rather high radiation exposure, only few side effects have been reported. However, blood cells are very sensitive to radiation. Therefore, it is important to determine how much radiation they received. Recently, the detection by immunofluorescence of the phosphorylation of the histone variant H2AX (γ‐H2AX) has been established as a reliable and sensitive technique to monitor DNA double-strand breaks (DSBs) in blood lymphocytes.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Delphine Denoyer
#375 How Long to Continue Surveillance in Patients Following ‘Curative Resection’ of Primary Small Bowel Tumors?
Introduction: Around 40-50% of patients with small bowel (SB) NETs have metastatic disease at the time of presentation. The majority of the remainder proceed to surgery for attempted curative resection. The optimal duration of surveillance post ‘curative surgical’ resection of primary SB NETs is unknown.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
#376 Resection of Primary Tumor Improves Survival in Small Bowel Neuroendocrine Tumors: A Single Center Experience
Introduction: Small bowel neuroendocrine tumors are uncommon tumors with an incidence of <0.5-1 per 100,000 population/year. We report on the survival rates of patients who had the primary tumor resected, to see whether primary tumor removal improves outcome.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
#377 Survival and Cause of Death in Patients with Small Bowel Neuroendocrine Tumors
Introduction: Small bowel neuroendocrine tumors (SB NETs) have a reported incidence of approximately 0.5-1 per 100 000 population/yr.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
#378 Does TNM Staging Classification Predict Survival in Patients with Small Bowel Neuroendocrine Tumors?
Introduction: Small bowel (SB) NETs are regarded as relatively indolent cancers. ENETS has published TNM staging. This study aims to demonstrate whether the TNM stage predicts survival in this cohort of patients.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
Keywords: TNM, survival
#452 Clinical and Psychometric Validation of the Disease-Specific Questionnaire Module (EORTC QLQ-GINET21) in Assessing Quality of Life of Patients with Neuroendocrine Tumors
Introduction: Quality of life (QoL) is an important outcome measure in clinical trials and is increasingly being used as an endpoint. The QLQ-GINET21 is a questionnaire developed with the EORTC QoL Group but which had not previously been validated.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr John Ramage
#575 Does the ENETS TNM staging criteria predict survival in patients with small bowel neuroendocrine tumours?
Introduction: A TNM staging system was designed by ENETS to stage small bowel NETs .(SBNETs)
Conference: 10th Annual ENETS Conference (2013)
Category: Clinical
Presenting Author: Dr Rajaventhan Srirajaskanthan
Keywords: Staging
#607 Goblet Cell Carcinoma of the Appendix: Acute v. Chronic Presentations
Introduction: Goblet Cell Carcinomas (GCC) are a rare neuroendocrine tumor (NET) of the appendix.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Ron Basuroy
#683 Liver Resection Experience for Metastatic Small Bowel NETs, a Single Center Experience
Introduction: Over the last two decades, the role of surgery in the management of small bowel NETs (SBNET) has evolved. There is growing evidence supporting the role of liver resection for metastatic disease.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Raj Srirajaskanthan
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.